Short-term Perfusion Angiography Pilot Study (SPA)

Peripheral Arterial Disease Clinical Trial

— SPA  

Official title:

Short-term 2D Perfusion Angiography Pilot Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03054636
• Other study ID #: 160201
• Status: Terminated
• Start date: January 2017
• Est. completion date: February 14, 2019

Study information

• Verified date: June 2020
• Source: Volcano Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Short term Perfusion Angiography (SPA) study is designed to collect 2D Perfusion data from Critical Limb Ischemia (CLI) endovascular (interventional) procedures for information on device performance in a real-world setting.

Description:

This clinical study is designed to collect pre and post procedural imaging data using 2D Perfusion (2DP) software in patients receiving an endovascular intervention.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 38
• Est. completion date: February 14, 2019
• Est. primary completion date: February 14, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject is = 18 years of age.

2. Subject or their legally authorized representative understands the research nature of the study and is willing and capable of providing informed consent

3. Subject has appropriate femoral arterial access

4. Subject presents with a Rutherford classification of 4 to 6.

5. Planned DSA with endovascular intervention below the knee on one or both limbs. This may include patients who undergo:

1. Above the knee (ATK) and below the knee (BTK) intervention during the same procedure.

2. Only BTK intervention.

3. ATK intervention with staged future BTK intervention within 6 weeks of the initial procedure.

Exclusion Criteria:

1. Subjects whose ATK intervention is limited to only the common femoral or iliac arteries

2. Subject is unwilling or unable to comply with the protocol including all follow-up visits

3. Subject with active atrial fibrillation at time of procedure

4. Critical limb ischemia due to acute arterial occlusion.

5. Subject with documented ejection fraction < 40% and/or prolonged bradycardia (< 60 beats per minute)

6. Inability to collect toe pressure on index limb from subject

7. Subjects with history of or known reaction or sensitivity to contrast agent that cannot be pre-medicated or any other condition that precludes an endovascular intervention and DSA

8. Female subject of childbearing potential who is pregnant (she must have negative pregnancy test within the 48 hours prior to enrollment), or plans a pregnancy during study period,

9. Subject life expectancy < 3 months,

10. Subject is participating in a potentially confounding device or drug clinical trial that interferes with this study

11. Investigator considers subject to be a poor candidate for the study or believes that the patient may compromise the study, e.g., concomitant conditions (reasons will be documented) )

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Locations

Country	Name	City	State
United States	University Hospitals	Cleveland	Ohio
United States	Miami Cardiac and Vascular Institute	Miami	Florida
United States	North Carolina Heart and Vascular	Raleigh	North Carolina
United States	Metro Health Hospital	Wyoming	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Volcano Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety (Freedom from Major Adverse Device Effects)	Freedom from Major Adverse Device Effects through 30 day visit.	30 days